Le Lézard
Classified in: Health
Subjects: POL, VET, FVT

Secretary of Veterans Affairs Dr. David Shulkin to Discuss Department's Efforts to Improve Care for America's Veterans at NPC Headliners Luncheon on November 6



WASHINGTON, Oct. 6, 2017 /PRNewswire-USNewswire/ -- As Veterans Day approaches, the Honorable Dr. David Shulkin, Secretary of Veterans Affairs will speak at a National Press Club Headliners Luncheon on Monday, November 6, 2017. Dr. Shulkin will discuss the Department's effort to care for millions of America's Veterans and improve the effectiveness of VA's healthcare system.

NATIONAL PRESS CLUB LOGO. (PRNewsFoto/NATIONAL PRESS CLUB) (PRNewsfoto/National Press Club)

Dr. Shulkin, the ninth Secretary of Veterans Affairs (VA), was confirmed by the Senate on February 13, 2017. Prior to his confirmation Dr. Shulkin served as VA's Under Secretary for Health for 18 months, leading the Nation's largest integrated health care system, with over 1,700 sites of care serving nearly nine million Veterans.

Lunch will be served in the club's Holeman Lounge at 12:30 p.m., with remarks beginning at 1 p.m., followed by a question-and-answer session ending at 2 p.m. Tickets cost $25 for National Press Club members (members may purchase two tickets at this rate) and $39 for all other non-member tickets. Please click here to purchase tickets to the luncheon.

Before serving with VA, Dr. Shulkin held numerous chief executive roles at Morristown Medical Center, and the Atlantic Health System Accountable Care Organization. He also served as President and CEO of Beth Israel Medical Center in New York City and has held numerous physician leadership roles including Chief Medical Officer of the University of Pennsylvania Health System, Temple University Hospital, and the Medical College of Pennsylvania Hospital. He has also held academic positions including Chairman of Medicine and Vice Dean at Drexel University School of Medicine.  

For all ticketing-related questions, please email reservations@press.org or call (202) 662-7501. Tickets must be paid for at the time of purchase. To submit a question for the speaker in advance, put VETERANS in the subject line and email to president@press.org. The deadline for submitting questions in advance is 10 a.m. on the day of the luncheon.

NPC Members who have a paid reservation to the Luncheon and wish to attend the pre-luncheon reception must send their RSVP via email to VIPreception@press.org at least 48 hours before the date of the Luncheon. Space may be limited.

The National Press Club is located on the 13th Floor of the National Press Building at 529 14th St., NW, Washington, D.C.

Contact:
Lindsay Underwood
lunderwood@press.org
(202) 662-7561

 

 

SOURCE National Press Club


These press releases may also interest you

at 04:00
According to Acuity Market Intelligence, border authorities have embraced digital identification and biometric-based automation to simplify and accelerate border control processing. Acuity's latest report on border control kiosks reveals that 71...

at 04:00
Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic...

at 03:15
High Hampton Holdings Corp. ("High Hampton" or the "Company") is pleased to announce that its Board of Directors has appointed David E. Argudo as new Chief Executive Officer to the Company. Mr. Argudo has been an invaluable asset to the Company in...

at 03:00
Results published in Diabetes, Obesity and Metabolism    Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes...

at 03:00
MedShr was commended at the Startups Awards in the Founders Pledge Social Impact and App of the Year categories   MedShr - The App for Doctors - has been Highly Commended in the Founders Pledge Social Impact Award and Commended in the App of the...

at 02:00
Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of...




News published on 6 october 2017 at 13:26 and distributed by: